

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/763,870	,870 02/28/2001		Xavier Forceville	569J US 3770	3493
466	7590	12/18/2001	•		
YOUNG & THOMPSON				EXAMINER	
745 SOUTH 23RD STREET 2ND FLOOR ARLINGTON, VA 22202			PAK, JOHN D		
				ART UNIT	PAPER NUMBER
				1616	- W
•				DATE MAILED: 12/18/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. **09/763.870** 

Applicantis

Forceville et al.

Examiner

Pak, J.

Art Unit 1616



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 1-22 4a) Of the above, claim(s) \_\_\_\_\_\_ is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) X Claim(s) 1-22 is/are rejected. 7) Claim(s) \_\_\_\_\_ is/are objected to. are subject to restriction and/or election requirement. 8) Claims \_\_\_ **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on \_\_\_\_\_\_ is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) X Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a)  $\boxtimes$  All b)  $\square$  Some\* c)  $\square$  None of: 1. Certified copies of the priority documents have been received. 2. U Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \*See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:

Serial Number: 09/763,870

Art Unit: 1616

Claims 1-22 are pending in this application.

Claims 1-15 provide for the "use of" selenium containing compounds, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 1-15 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Because a "use of" a compound is not a statutorily recognized class of invention, no further examination on the merits can be made on claims 1-15.

Claims 16-22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

(1) Claims 16-22 are directed to a composition invention. The composition is set forth in terms of a daily dose. This is an improper method feature in a composition invention. A daily dose does not, and cannot, change the composition per se. A daily dose is practiced in the context of a method. Therefore, the claims are indefinite to the extent that they read on a composition with a daily dose feature.

Serial Number: 09/763,870

Art Unit: 1616

(2) In claim 16, lines 3-4, features recited in terms of "i.e." is improper. Every feature must be positively set forth, not vaguely referenced in terms of "i.e."

(3) Even without the "i.e." problem, 2-80 mg selenium daily is not equivalent to 0.025 to 1 mg/kg.

- (4) In claim 20, "those cited above" is improper claim language.
- (5) In claim 21, a preferable feature should not be recited next to a non-preferred feature.

  A further dependent claim is suggested.
- (6) In claim 21, "also subcutaneous or intramuscular" should be rephrased to avoid the use of "also."
- (7) In claim 22, "in the form of a perfusion" is confusing. Does applicant mean the liquid that has been forced through the organ or tissue?

For these reasons no claim can be allowed at this time.

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Examiner Pak whose telephone number is (703) 308-4538. The Examiner can normally be reached on Monday through Thursday from 8:00 AM to 5:30 PM. The Examiner can also be reached on alternate Fridays.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

JOHN PAK
PRIMARY EXAMINER
GROUP 1890